Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr. Sally Seymour ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Two U.S. Navy pilots ejected from their jet fighter over the Red Sea after being caught in "an apparent case of friendly-fire," U.S. Central Command said Sunday, as American forces conducted a new ...

In another milestone, Eli Lilly's weight-loss medication, Zepbound, received FDA approval, marking it as the first drug to specifically tackle moderate to severe obstructive sleep apnea in obese ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.